Great news today - a step in the RC220 process we have all eagerly been awaiting.
"RC220 prevents drug precipitation and phlebitis when infused into peripheral veins."
The health benefits to patients and commercial benefits to RAC cannot be understated here, peripheral infusion is a MUST for solid tumours in today's clinical practice.
Congratulations to the RAC team for executing this, what an incredibly complex problem that's been solved. From a scientific point of view I'd love to know how they did it, but guess I'll have to wait
I feel my confidence in RAC slowly returning to the levels it was when I first bought back in 2021. Very keen to see the updated strategy and plans on getting RC220 into the clinic.
